Table 2.
High-grade risk factors associated with the detection of high-grade precancerous or cancerous pancreatic lesions in score positive patients
| Without lesions (n=511) | PHP (n=10) | P (PHP vs. without lesions) | Resectable lesions (n=20) | P (resectable lesions vs. without lesions) | All lesions (n=33) | P (all lesions vs. without lesions) (univariate/multivariate logistic analysis) | |
|---|---|---|---|---|---|---|---|
| HGRF factor, n (%) | |||||||
| Familial PC | 6 (1.2) | 0 | 0.999 | 0 | 0.999 | 0 | 0.999 |
| New-onset DM | 39 (7.6) | 1 (10.0) | 0.781 | 3 (15.0) | 0.242 | 6 (18.2) | 0.040*/0.268 |
| Jaundice | 13 (2.5) | 0 | 0.999 | 2 (10.0) | 0.069 | 4 (12.1) | 0.006*/0.441 |
| Tumor biomarkers | 131 (25.6) | 2 (20.0) | 0.687 | 9 (45.0) | 0.061 | 22 (66.7) | <0.001*/0.003* |
| Chronic pancreatitis | 22 (4.3) | 0 | 0.998 | 0 | 0.998 | 0 | 0.998 |
| Medical history of IPMN | 76 (14.9) | 2 (20.0) | 0.654 | 4 (20.0) | 0.532 | 4 (12.1) | 0.666 |
| Medical history of pancreatic cyst | 109 (21.3) | 3 (30.0) | 0.512 | 4 (20.0) | 0.887 | 4 (12.1) | 0.214 |
| Hereditary PC syndrome/pancreatitis | 0 | 0 | NA | 0 | NA | 0 | NA |
| MPD dilation | 41 (8.0) | 2 (20.0) | 0.192 | 4 (20.0) | 0.071 | 5 (15.2) | 0.162 |
| Score valuation | |||||||
| Mean HGRS±SD, point | 0.9±0.6 | 1.0±0.5 | 0.417 | 1.3±0.9 | 0.001* | 1.4±0.8 | <0.001*/0.355 |
| HGRS≥1 point, n (%) | 377 (73.8) | 9 (90.0) | 0.272 | 18 (90.0) | 0.122 | 31 (93.9) | 0.020*/0.692 |
*P<0.05 compared to patients without pancreatic high-grade precancerous lesion and PC. DM: Diabetes mellitus; HGRF: High-grade risk factors; HGRS: High-grade risk score; IPMN: Intraductal papillary mucinous neoplasm; MPD: Main pancreatic duct; NA: No assessment; PC: Pancreatic cancer; PHP: Pancreatic high-grade precancerous lesion; SD: Standard deviation